STOCK TITAN

[SCHEDULE 13G/A] Madrigal Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Janus Henderson Group plc reports beneficial ownership of 2,191,753 shares of Madrigal Pharmaceuticals common stock, representing 9.9% of the class. The filing breaks this down by reporting persons and subsidiaries: JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%), and the reporting tables show shared voting and shared dispositive power over 2,191,753 shares with no sole voting or dispositive power.

The filer certifies these holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports on the company’s behalf.

Janus Henderson Group plc dichiara la titolarità effettiva di 2,191,753 azioni ordinarie di Madrigal Pharmaceuticals, pari al 9,9% della categoria. La comunicazione specifica la ripartizione per le persone che presentano la segnalazione e per le controllate: JHIUS può essere considerata titolare effettiva di 2,173,828 azioni (9,8%), e le tabelle di segnalazione mostrano potere di voto e potere dispositivo condivisi su 2,191,753 azioni, senza alcun potere di voto o dispositivo esclusivo.

Il dichiarante certifica che queste partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attività e non con l'obiettivo di cambiare o influenzare il controllo. Il deposito include inoltre una procura che autorizza i funzionari di compliance nominati a presentare, per conto della società, i rapporti di proprietà richiesti.

Janus Henderson Group plc informa de la propiedad beneficiaria de 2,191,753 acciones ordinarias de Madrigal Pharmaceuticals, equivalentes al 9,9% de la clase. El expediente desglosa esto por las personas que informan y por las subsidiarias: JHIUS puede considerarse propietario beneficiario de 2,173,828 acciones (9,8%), y las tablas de informe muestran voto compartido y poder de disposición compartido sobre 2,191,753 acciones, sin poder de voto ni de disposición exclusivo.

El presentador certifica que estas participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con la finalidad de cambiar o influir en el control. El expediente incluye asimismo un poder que autoriza a los oficiales de cumplimiento nombrados a presentar los informes de propiedad exigidos en nombre de la compañía.

Janus Henderson Group plc는 Madrigal Pharmaceuticals 보통주 2,191,753주(해당 주식군의 9.9%)에 대한 실질적 소유를 보고했습니다. 제출서류는 보고인 및 자회사를 기준으로 이를 세부 분류합니다: JHIUS는 2,173,828주(9.8%)의 실질적 소유자로 간주될 수 있으며, 보고 표에는 2,191,753주에 대해 공동 의결권 및 공동 처분권이 있음으로 기재되어 있고 단독 의결권이나 단독 처분권은 없습니다.

신고인은 이 보유가 영업의 통상적인 범위 내에서 취득·보유된 것이며 지배권을 변경하거나 영향력을 행사할 목적이 아님을 증명합니다. 제출서류에는 또한 회사 명의로 필요한 소유 보고서를 작성·제출할 수 있도록 지정된 컴플라이언스 담당자들에게 위임하는 위임장도 포함되어 있습니다.

Janus Henderson Group plc déclare la propriété bénéficiaire de 2,191,753 actions ordinaires de Madrigal Pharmaceuticals, soit 9,9 % de la catégorie. Le dossier détaille cette répartition par personnes déclarante et filiales : JHIUS peut être considéré comme propriétaire bénéficiaire de 2,173,828 actions (9,8 %), et les tableaux de déclaration indiquent un pouvoir de vote partagé et un pouvoir de disposition partagé sur 2,191,753 actions, sans pouvoir de vote ni de disposition exclusif.

Le déclarant certifie que ces positions ont été acquises et sont détenues dans le cadre normal des activités et non dans le but de modifier ou d'influencer le contrôle. Le dépôt inclut également une procuration autorisant les responsables conformité nommés à signer, au nom de la société, les rapports de propriété requis.

Janus Henderson Group plc meldet wirtschaftliches Eigentum an 2,191,753 Stammaktien von Madrigal Pharmaceuticals, was 9,9% der Klasse entspricht. Die Meldung gliedert dies nach meldenden Personen und Tochtergesellschaften: JHIUS kann als wirtschaftlicher Eigentümer von 2,173,828 Aktien (9,8%) angesehen werden, und die Meldetabellen weisen gemeinsame Stimm- und gemeinsame Verfügungsrechte über 2,191,753 Aktien aus, ohne alleinige Stimm- oder Verfügungsrechte.

Der Einreicher bestätigt, dass diese Bestände im normalen Geschäftsbetrieb erworben und gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle dienen. Die Meldung enthält außerdem eine Vollmacht, die benannte Compliance-Beauftragte ermächtigt, die erforderlichen Besitzmeldungen im Namen des Unternehmens zu unterzeichnen.

Positive
  • Material stake disclosed: Aggregate beneficial ownership of 2,191,753 shares (9.9%) provides clear investor visibility.
  • Certifies passive intent: The filing states the shares are held in the ordinary course and not for the purpose of changing control, clarifying intent.
Negative
  • None.

Insights

TL;DR: Janus Henderson discloses a near-10% stake in Madrigal with shared voting and dispositive power—material but presented as non-control holdings.

Janus Henderson Group plc reports an aggregate beneficial ownership of 2,191,753 shares (9.9%). The filing specifies 0 shares of sole voting or sole dispositive power and 2,191,753 shares of shared voting and shared dispositive power, consistent with pooled/managed-account ownership structures. JHIUS is identified as an indirect subsidiary potentially deemed beneficial owner of 2,173,828 shares (9.8%). The filer includes an explicit certification that the shares are held in the ordinary course of business and not to influence control, which frames the position as passive rather than activist.

TL;DR: A single institutional group holds a meaningful equity stake near the 10% threshold while disclaiming intent to affect control.

The disclosure is thorough: it identifies reporting entities, quantifies shared voting/dispositive powers, and attaches a power-of-attorney authorizing compliance officers to file on behalf of the parent. For governance review, notable facts are the shared voting control of 2,191,753 shares and the formal statement that holdings were "not acquired or held for the purpose of changing or influencing the control" of the issuer. These elements are relevant for assessing potential influence and for monitoring any future schedule amendments.

Janus Henderson Group plc dichiara la titolarità effettiva di 2,191,753 azioni ordinarie di Madrigal Pharmaceuticals, pari al 9,9% della categoria. La comunicazione specifica la ripartizione per le persone che presentano la segnalazione e per le controllate: JHIUS può essere considerata titolare effettiva di 2,173,828 azioni (9,8%), e le tabelle di segnalazione mostrano potere di voto e potere dispositivo condivisi su 2,191,753 azioni, senza alcun potere di voto o dispositivo esclusivo.

Il dichiarante certifica che queste partecipazioni sono state acquisite e sono detenute nell'ordinario svolgimento dell'attività e non con l'obiettivo di cambiare o influenzare il controllo. Il deposito include inoltre una procura che autorizza i funzionari di compliance nominati a presentare, per conto della società, i rapporti di proprietà richiesti.

Janus Henderson Group plc informa de la propiedad beneficiaria de 2,191,753 acciones ordinarias de Madrigal Pharmaceuticals, equivalentes al 9,9% de la clase. El expediente desglosa esto por las personas que informan y por las subsidiarias: JHIUS puede considerarse propietario beneficiario de 2,173,828 acciones (9,8%), y las tablas de informe muestran voto compartido y poder de disposición compartido sobre 2,191,753 acciones, sin poder de voto ni de disposición exclusivo.

El presentador certifica que estas participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con la finalidad de cambiar o influir en el control. El expediente incluye asimismo un poder que autoriza a los oficiales de cumplimiento nombrados a presentar los informes de propiedad exigidos en nombre de la compañía.

Janus Henderson Group plc는 Madrigal Pharmaceuticals 보통주 2,191,753주(해당 주식군의 9.9%)에 대한 실질적 소유를 보고했습니다. 제출서류는 보고인 및 자회사를 기준으로 이를 세부 분류합니다: JHIUS는 2,173,828주(9.8%)의 실질적 소유자로 간주될 수 있으며, 보고 표에는 2,191,753주에 대해 공동 의결권 및 공동 처분권이 있음으로 기재되어 있고 단독 의결권이나 단독 처분권은 없습니다.

신고인은 이 보유가 영업의 통상적인 범위 내에서 취득·보유된 것이며 지배권을 변경하거나 영향력을 행사할 목적이 아님을 증명합니다. 제출서류에는 또한 회사 명의로 필요한 소유 보고서를 작성·제출할 수 있도록 지정된 컴플라이언스 담당자들에게 위임하는 위임장도 포함되어 있습니다.

Janus Henderson Group plc déclare la propriété bénéficiaire de 2,191,753 actions ordinaires de Madrigal Pharmaceuticals, soit 9,9 % de la catégorie. Le dossier détaille cette répartition par personnes déclarante et filiales : JHIUS peut être considéré comme propriétaire bénéficiaire de 2,173,828 actions (9,8 %), et les tableaux de déclaration indiquent un pouvoir de vote partagé et un pouvoir de disposition partagé sur 2,191,753 actions, sans pouvoir de vote ni de disposition exclusif.

Le déclarant certifie que ces positions ont été acquises et sont détenues dans le cadre normal des activités et non dans le but de modifier ou d'influencer le contrôle. Le dépôt inclut également une procuration autorisant les responsables conformité nommés à signer, au nom de la société, les rapports de propriété requis.

Janus Henderson Group plc meldet wirtschaftliches Eigentum an 2,191,753 Stammaktien von Madrigal Pharmaceuticals, was 9,9% der Klasse entspricht. Die Meldung gliedert dies nach meldenden Personen und Tochtergesellschaften: JHIUS kann als wirtschaftlicher Eigentümer von 2,173,828 Aktien (9,8%) angesehen werden, und die Meldetabellen weisen gemeinsame Stimm- und gemeinsame Verfügungsrechte über 2,191,753 Aktien aus, ohne alleinige Stimm- oder Verfügungsrechte.

Der Einreicher bestätigt, dass diese Bestände im normalen Geschäftsbetrieb erworben und gehalten werden und nicht zum Zweck der Änderung oder Beeinflussung der Kontrolle dienen. Die Meldung enthält außerdem eine Vollmacht, die benannte Compliance-Beauftragte ermächtigt, die erforderlichen Besitzmeldungen im Namen des Unternehmens zu unterzeichnen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many Madrigal (MDGL) shares does Janus Henderson report owning?

The reporting group discloses aggregate beneficial ownership of 2,191,753 shares, representing 9.9% of the class.

Does Janus Henderson have sole voting power over MDGL shares?

No. The filing shows 0 shares with sole voting power and 2,191,753 shares with shared voting power.

Which subsidiary is identified as a beneficial owner of MDGL shares?

The filing states that JHIUS may be deemed the beneficial owner of 2,173,828 shares (9.8%).

Is Janus Henderson holding these shares to influence company control?

The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control.

Who signed the Schedule 13G/A for Janus Henderson?

The filing is signed by Kristin Mariani, Head of North America Compliance, CCO on behalf of Janus Henderson Group plc.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Latest SEC Filings

MDGL Stock Data

8.32B
20.52M
7.73%
108.31%
17.06%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN